These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36648324)

  • 21. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
    Pirosa MC; Stathis A; Zucca E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
    Abdulhaq H; Hwang A; Mahmood O
    Onco Targets Ther; 2023; 16():617-629. PubMed ID: 37492075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
    Cherng HJ; Westin JR
    Clin Cancer Res; 2022 Sep; 28(18):3908-3910. PubMed ID: 35861632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of tafasitamab in diffuse large B-cell lymphoma.
    Düll J; Topp M; Salles G
    Ther Adv Hematol; 2021; 12():20406207211027458. PubMed ID: 34285786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line treatment of diffuse large B-cell lymphoma: Evolution of options.
    Fabbri N; Mussetti A; Sureda A
    Semin Hematol; 2023 Nov; 60(5):305-312. PubMed ID: 38342663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Harris LJ; Patel K; Martin M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.
    Messori A; Caccese E
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4666-4670. PubMed ID: 35856357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
    Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
    Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
    Camus V; Houot R; Brisou G; Tessoulin B; Bailly S; Sesques P; Decroocq J; Krzisch D; Oberic L; Lemonnier F; Bouabdallah K; Campidelli A; Tounes L; Abraham J; Herbaux C; Morschhauser F; Damaj GL; Guidez S; Carras S; Fornecker LM; Choquet S; Hermine O; Paillassa J; Chauchet A; Casasnovas O; Drieu La Rochelle L; Castilla-Llorente C; Joris M; Dupont V; Marquet A; Le Gouill S; Jardin F
    Blood Adv; 2024 Oct; 8(20):5371-5381. PubMed ID: 39163620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report.
    Nasir SA; Pandya D; Wojkiewicz S; Khandpur B; Downes E; Pathare P; Frank R
    Cureus; 2022 Dec; 14(12):e32403. PubMed ID: 36636536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
    Ward JP; Berrien-Elliott MM; Gomez F; Luo J; Becker-Hapak M; Cashen AF; Wagner-Johnston ND; Maddocks K; Mosior M; Foster M; Krysiak K; Schmidt A; Skidmore ZL; Desai S; Watkins MP; Fischer A; Griffith M; Griffith OL; Fehniger TA; Bartlett NL
    Blood; 2022 Mar; 139(13):1999-2010. PubMed ID: 34780623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
    Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
    Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
    Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
    Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
    Varma G; Goldstein J; Advani RH
    Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Brooks TR; Caimi PF
    Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.